Abstract
While dematiaceous (dark-walled) fungi are ubiquitous in the environment, their involvement in invasive human infections has rarely been reported. However, these organisms have been identified as potential emerging pathogens, particularly among immunocompromised hosts. We describe a diabetic patient with Lecythophora mutabilis prosthetic valve endocarditis who was treated surgically, as well as with amphotericin B lipid complex and voriconazole, which were subsequently followed by prolonged voriconazole suppressive therapy. To the best of our knowledge, our patient is the first reported survivor of L. mutabilis prosthetic valve endocarditis.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Amphotericin B / therapeutic use
-
Antifungal Agents / therapeutic use
-
Aortic Valve / surgery
-
Ascomycota / classification
-
Ascomycota / genetics
-
Ascomycota / isolation & purification*
-
Diabetes Complications*
-
Drug Combinations
-
Endocarditis / drug therapy
-
Endocarditis / microbiology*
-
Endocarditis / surgery
-
Heart Valve Prosthesis / adverse effects
-
Heart Valve Prosthesis / microbiology*
-
Humans
-
Male
-
Middle Aged
-
Molecular Sequence Data
-
Mycoses / drug therapy
-
Mycoses / microbiology
-
Mycoses / surgery
-
Phosphatidylcholines / therapeutic use
-
Phosphatidylglycerols / therapeutic use
-
Prosthesis-Related Infections / drug therapy
-
Prosthesis-Related Infections / microbiology*
-
Prosthesis-Related Infections / surgery
-
Pyrimidines / therapeutic use
-
Sequence Analysis, DNA
-
Treatment Outcome
-
Triazoles / therapeutic use
-
Voriconazole
Substances
-
Antifungal Agents
-
Drug Combinations
-
Phosphatidylcholines
-
Phosphatidylglycerols
-
Pyrimidines
-
Triazoles
-
liposomal amphotericin B
-
Amphotericin B
-
Voriconazole